Sotorasib: KRAS G12C inhibitor drugs & full guide
Sotorasib is a breakthrough antitumor medication and the world's first approved inhibitor targeting the KRAS G12C mutation. Historically considered an "undruggable" target, the development of Sotorasib has shifted the treatment paradigm for non-small cell lung cancer.
The substance selectively binds to the mutated KRAS protein, effectively locking it in an inactive state and halting tumor proliferation. On Unifarm, you can access a verified list of available medications containing Sotorasib for order.
Indications
- Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Specifically indicated for tumors harboring the KRAS G12C mutation (confirmed by an FDA-approved test).
- Prescribed for patients who have received at least one prior systemic therapy (chemotherapy or immunotherapy).
Dosage and administration
The recommended dosage is 960 mg (typically eight 120 mg tablets) orally once daily, at the same time each day, with or without food.
Key Guidelines:
- Swallow tablets whole; do not chew, crush, or split them.
- If a dose is missed by more than 6 hours, skip it and resume the schedule the next day.
- Dose reduction (to 480 mg or 240 mg) is managed by a physician based on toxicity levels.
- Severe hypersensitivity to Sotorasib or its components.
- Pregnancy and breastfeeding (potential for fetal harm).
- Pediatric use under 18 years of age.
- Severe hepatic impairment (strict monitoring is required).
Common adverse reactions to monitor include:
- Gastrointestinal: Diarrhea, nausea, vomiting (hydration monitoring is advised).
- Liver: Hepatotoxicity (elevated ALT/AST levels), requiring regular liver function tests.
- Musculoskeletal: Bone or muscle pain, fatigue.
- Respiratory: Rare cases of Interstitial Lung Disease (ILD) / pneumonitis.
List of medicines by active substance Sotorasib
✅ All products loaded (2)